COVID-19 Memorandums for Division of Cancer Prevention Investigators
- COVID Minor Deviation Reporting Form (
XLS, 75 KB)
Date: May 8, 2020
- Additional Guidance Regarding Reporting of Minor Deviations for Clinical Trials Supported by the NCI DCP Phase 0-2 Cancer Prevention Clinical Trials Program (PDF, 90 KB)
Date: March 27, 2020
- Interim Guidance for Patients on Clinical Trials Supported by the NCI DCP Phase 0-2 Cancer Prevention Clinical Trials Program (PDF, 84 KB)
Date: March 13, 2020
PLEASE NOTE: This is a reminder that infections occurring in subjects on clinical trials are considered adverse events, please see this additional guidance for reporting COVID-19 related adverse event.
The Cancer Prevention Clinical Trials Network (CP-CTNet) performs early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (micro-dosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials. The goal is to identify safe and effective preventive interventions in order to advance their further clinical development for cancer prevention.
Welcome to the CP-CTNet Newsletter where we share programmatic and research updates for the Cancer Prevention Clinical Trials Network (CP-CTNet).
View the latest issue
(PDF, 2.34 MB)
POSTED: December 2021
The goals of the Network are:
- Design and conduct early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (micro-dosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials;
- Characterize the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlation of these effects with clinical endpoints; and
- Develop further scientific insights into the mechanisms of cancer prevention by the agents examined, including the development of novel potential markers as determinants of response.
The CP-CTNet Sites provide scientific leadership in development and conduct of early phase cancer prevention clinical trials as well as in the management and analysis of the data. The medical research centers that will lead studies are listed below.
Funded in 2019:
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northwestern Cancer Prevention Consortium, Northwestern Cancer Prevention Consortium, led by Seema A. Khan, M.D.
- University of Arizona, University of Arizona Cancer Prevention Clinical Trials Network (UA CP-CTNet), led by H. H. Sherry Chow, Ph.D. and Julie Bauman, M.D., M.P.H.
- University of Texas MD Anderson Cancer Center, iCAN-PREVENT: International Cancer Prevention Clinical Trial Consortium, led by Powel H. Brown, M.D. and Eduardo Vilar-Sanchez, M.D., Ph.D.
Funded in 2020:
- University of Michigan, Early Phase Clinical Cancer Prevention Consortium, led by Dean Brenner, M.D. and Zora Djuric, Ph.D.
- University of Wisconsin, The MW Chemoprevention Network, led by Howard Bailey, M.D.
A coordinating center to support the CP-CTNet Sites and coordinate trans-Network activities was funded in fall 2019. The Data Management, Auditing and Coordinating Center (DMACC) is located at:
- The University of Wisconsin-Madison, led by KyungMann Kim, Ph.D.
This website is designed to help potential applicants find resources related to the two companion funding opportunity announcements (FOA) in support of CP-CTNet.